Business Context and Reporting Period
This Form 6-K filing by Mereo Biopharma Group Plc covers the month of May 2022, with the report dated May 25, 2022. The filing addresses a regulatory notification regarding the listing status of the Company's American Depositary Shares (ADSs) on the Nasdaq Global Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a listing deficiency and does not contain financial performance data.
Material Changes
The material change disclosed is the receipt of a Notification Letter from Nasdaq on May 23, 2022. The Company's ADSs failed to maintain the minimum bid price of $1.00 over the previous 30 consecutive business days. This failure does not result in immediate delisting, and trading continues uninterrupted under the symbol "MREO."
Guidance, Outlook, and Risks
- Compliance Period: The Company has 180 calendar days, until November 21, 2022, to regain compliance with the minimum bid price requirement.
- Compliance Criteria: To close the matter, the closing bid price per ADS must be at least $1.00 for a minimum of 10 consecutive business days during the Compliance Period.
- Grace Period: If compliance is not met by November 21, 2022, the Company may be eligible for an additional 180-day grace period, contingent on meeting the market value of publicly held shares and other initial listing standards.
- Delisting Risk: Failure to regain compliance during the initial grace period and ineligibility for an additional grace period will result in written notice of delisting. The Company may appeal such a determination.
- Management Commentary: The Company states it intends to monitor the closing bid price and asserts that its business operations are not affected by the Notification Letter.
Key Facts for Investor Verification
- Verify the current closing bid price of Mereo Biopharma Group Plc ADSs to assess progress toward the $1.00 threshold.
- Monitor the Company's ability to maintain a bid price of at least $1.00 for 10 consecutive business days before November 21, 2022.
- Review the Company's market value of publicly held shares to determine eligibility for a potential second grace period.
- Confirm that trading of ADSs under the symbol "MREO" remains uninterrupted despite the notification.